Aminoglycoside extended interval dosing in neonates is safe and effective: a meta-analysis

E Nestaas, H-J Bangstad, L Sandvik, K-O Wathne

Objectives: To review the evidence from controlled clinical trials of neonates given equal daily aminoglycoside doses as extended interval dosing (dosage interval typically 24 hours in term and 36–48 hours in immature neonates) compared with traditional dosing (dosage interval typically 8–12 hours in term and 12–24 hours in immature neonates).

Design: Systematic review and meta-analysis of controlled trials found in electronic databases, trial registers, and references in reviews and selected trials.

Settings: The selected trials were blinded and assessed for methodological quality. Each trial’s own predefined criteria for treatment failure, nephrotoxicity, ototoxicity, and therapeutic serum drug concentrations were used.

Subjects: Controlled trials of neonatal aminoglycoside treatment in which equal aminoglycoside daily doses were given at traditional and extended dosage intervals.

Main outcome measures: Serum drug concentrations outside the therapeutic range. Treatment failure and toxicity.

Results: Sixteen trials involving 823 neonates met the inclusion criteria for the systematic review. Twelve trials involving 698 neonates were included in the meta-analysis of the pharmacokinetics. Compared with traditional dosing, extended interval dosing was associated with a significantly lower risk of both peak (summary risk ratio 0.50, 95% confidence interval 0.26 to 0.94) and trough (0.36, 0.25 to 0.56) serum drug concentrations outside the therapeutic range. Accurate information on treatment failure was obtained in nine trials involving 555 neonates. One trial reported treatment failure. In this trial two neonates in the traditional dosing group did not respond to treatment within 72 hours. Nephrotoxicity was investigated in 589 neonates in 12 trials and ototoxicity in 210 neonates in four trials, with no significant differences between the two dosing regimens.

Conclusions: Extended interval dosing of aminoglycosides in neonates is safe and effective, with a reduced risk of serum drug concentrations outside the therapeutic range.

Aminoglycosides, usually combined with a betalactam, are widely used for neonatal sepsis. The serum drug concentration (SDC) should be within the therapeutic range to secure effect and avoid toxicity. In adult patients, an early peak high SDC has been associated with an improved clinical outcome in severe infections.1 In extended interval dosing (EID) a higher dose is given less frequently than in traditional dosing (TD). Meta-analysis of trials in adults and children have shown equal or better performance with EID than with TD.2–9 Several trials have addressed the pharmacokinetic performance of EID compared with TD in neonates, often without sufficient statistical power. The dose and dosage interval for neonatal aminoglycoside dosing varies widely among guidelines. We have carried out a systematic review of controlled trials in neonates given aminoglycosides as EID or TD. We compared efficacy and toxicity and performed a meta-analysis of the pharmacokinetics based on each trial’s own predefined criteria for treatment failure, nephrotoxicity, ototoxicity, and therapeutic SDC.

METHODS

Search strategy
The databases Biosis, Cochrane, Embase, and Medline were searched from their inception to October 2004. Trials in any language were considered. References in reviews and the trials found were searched manually. Electronic trial registers were searched for unpublished and ongoing trials (details shown in box 1). The manufacturers of aminoglycosides were not contacted for unpublished trials.

Selection
Controlled clinical trials were evaluated for inclusion on the basis of the study design, the target population, and the end points reported (box 2). In trials with subgroups fulfilling the criteria, these were included if data extraction was possible.

Data extracted
From each trial, the following data were extracted: inclusion criteria, type of aminoglycoside used, dose and dosage interval, therapeutic range for peak and trough SDC, number of neonates evaluated, prevalence of therapeutic SDC, toxicity, and clinical cure rate.

Data abstraction
EN performed the search and blinded the trials. HJB and KOW independently filled in a form for data extraction and assessed the presence of possible systematic errors10 in each trial. Disagreements were solved by consensus. Data were extracted from final reports, except for one question concerning clinical cure rate. Some authors did not report clinical cure rate completely and were contacted by mail or email for additional information.

Abbreviations: CI, confidence interval; EID, extended interval dosing, typically 4–5 mg/kg gentamicin given to neonates at dosage interval 24 hours or longer; SDC, serum drug concentration; TD, traditional dosing, typically 2–3 mg/kg gentamicin given to neonates at dosage interval 8–24 hours.
random effects model being more suitable than the fixed effects model, and we chose the same level of significance for heterogeneity between subgroups. In the case of no events, 0.5 was added to each cell of the table. We performed a subgroup analysis based on the a priori hypothesis that the therapeutic peak SDC range chosen could influence the difference in pharmacokinetic performance between the EID and TD groups. Two sided p values and 95% confidence intervals (CI) were used. We performed tests for the presence of publication bias (funnel plot asymmetry) and sensitivity analyses for design (randomised versus other trials) and internal validity (bias versus no bias). The regression analyses for funnel plot asymmetry were performed using SPSS 11.0.0 for Windows. All other analyses were performed using EasyMA.

RESULTS

We found 16 trials from which data for 823 neonates could be used (table 1). In five trials only a subgroup of neonates fulfilled our inclusion criteria. All trials were found in electronic databases.

Trial characteristics

Eleven of the trials had a prospective randomised design, four had a historical control group, and one had a cohort design. Asphyxia, risk of deafness, kidney malformations, and concomitant use of potentially nephrotoxic or otoxic drugs were often used exclusion criteria. Amikacin was studied in two trials. In all other trials, gentamicin was used. The daily amikacin dose was 15 mg/kg in both trials. The daily gentamicin dose was 2.5–5 mg/kg. The dosage interval was 12 hours in the TD group and 24 hours in the EID group in all but two trials. Gooding et al used a 24 hour TD dosage interval and 36 hour EID dosage interval, and Mercado et al compared 24 hours in the TD group with 48 hours in the EID group.

Methodological quality assessment

In general, design and methodology were seldom completely reported. Often the process of randomisation and the blinding towards both the caregivers and those determining outcome was not described. Four trials used a historical control group. In two trials the control group consisted of neonates given aminoglycoside treatment within a specified
Quantitative data synthesis

SDCs inside and outside the therapeutic range were described sufficiently for inclusion in the meta-analysis in 12 of 16 trials\(^{16} 17 20–27 30 31\) (table 2). We used SDCs assessed at the most equal point of time in the two groups, preferably 48–72 hours after start of treatment. Eleven trials\(^{16} 17 20–27 31\) used gentamicin and one\(^{16}\) used amikacin.

When combining all trials, 91 of 355 (25.6%) peak SDCs in neonates given TD and 28 of 343 (8.2%) in neonates given EID were outside the therapeutic range. The summary risk ratio for peak SDC outside the therapeutic range was 0.50 (95% CI 0.26 to 0.94, \(p = 0.033\)). A total of 108 of 355 (30.4%) trough SDCs in the TD group and 21 of 343 (6.1%) in the EID group were outside the therapeutic range. The summary risk ratio was 0.36 (95% CI 0.25 to 0.56, \(p<0.001\)). No clear evidence of publication bias\(^{13}\) was found for either peak or trough risk ratio (\(p>0.10\)).

The therapeutic peak range

Adequate peak SDC, for gentamicin and tobramycin above 5 mg/l and for amikacin above 20 mg/l, has in adult patients been associated with an improved clinical outcome in severe infections.\(^1\) In the four trials\(^{19–22}\) accepting lower peak SDC in the TD group, the summary peak risk ratio showed no significant difference between the two dosing regimens (fig 1). The summary risk ratio was 1.12 (95% CI 0.56 to 2.24, \(p = 0.76\)).

In the trials aiming at a higher peak SDC, the summary peak risk ratio was significantly in favour of EID (0.38; 95% CI 0.24 to 0.61; \(p<0.001\)). The difference in summary risk ratio between these subgroups was significant (\(p<0.01\)).

Design

There were significant differences in peak risk ratio between randomised and non-randomised trials (\(p<0.1\)) (fig 2). The summary peak risk ratio in the randomised trials was 0.84 (95% CI 0.43 to 1.58, \(p = 0.60\)). When the trials with low therapeutic peak range\(^{20–23}\) were excluded, the summary risk ratio was 0.28 (95% CI 0.07 to 1.12, \(p = 0.072\)). The non-randomised trials all had high therapeutic peak range, and the summary risk ratio for these trials was 0.40 (95% CI 0.24 to 0.66, \(p<0.001\)). There was no significant difference in summary peak risk ratio between randomised and non-randomised trials when trials with low therapeutic peak range were excluded (\(p=0.1\)).

There were no significant differences in summary trough risk ratios between randomised and non-randomised trials (\(p>0.1\)) (fig 3). The summary trough risk ratio was significantly in favour of EID for the six randomised trials (0.42; 95% CI 0.26 to 0.66; \(p<0.001\)).

Bias in internal validity

There were no significant differences in summary peak or trough risk ratio between trials with and without systematic errors (\(p>0.1\)). In trials without systematic errors the summary peak risk ratio was 0.35 (95% CI 0.08 to 1.51, \(p = 0.16\)). The summary trough risk ratio was 0.24 (95% CI 0.04 to 1.69, \(p = 0.15\)).

---

Table 1  Design, inclusion criteria, and number of neonates included from the relevant trials (see box 3 for criteria used for evaluation on systematic errors

<table>
<thead>
<tr>
<th>Trial</th>
<th>Year published</th>
<th>Kind of control group</th>
<th>Gestational age (weeks)</th>
<th>Birth weight (g)</th>
<th>Daily dose (EID/TD)</th>
<th>Number of neonates included</th>
<th>Trough SDC range (mg/l)</th>
<th>Systematic errors in internal validity</th>
<th>Therapeutic peak SDC range (mg/l)</th>
<th>Therapeutic trough SDC range (mg/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coeling et al(^{16})</td>
<td>2001</td>
<td>Historical</td>
<td>&lt; 28</td>
<td>&gt; 750–1500</td>
<td>2.6/2.5</td>
<td>57</td>
<td>0.1–1.5</td>
<td>Yes</td>
<td>Gentamicin 2.67/2.5</td>
<td>36/24</td>
</tr>
<tr>
<td>Mercado et al(^{*})</td>
<td>2001</td>
<td>Randomised</td>
<td>&gt; 34</td>
<td>&gt; 0000</td>
<td>2.5/2.5</td>
<td>7</td>
<td>0.2–0.2</td>
<td>No</td>
<td>Gentamicin 2.5/2.5</td>
<td>48/24</td>
</tr>
<tr>
<td>Kosalaraksa et al(^{22})</td>
<td>2000</td>
<td>Randomised</td>
<td>&lt; 34</td>
<td>&gt; 2500</td>
<td>4/5</td>
<td>61</td>
<td>0.2–0.2</td>
<td>No</td>
<td>Gentamicin 4/5</td>
<td>24/12</td>
</tr>
<tr>
<td>Chotigeat et al(^{22})</td>
<td>2000</td>
<td>Randomised</td>
<td>&gt; 34</td>
<td>&gt; 0000</td>
<td>4–5/4–5</td>
<td>15</td>
<td>0–0</td>
<td>No</td>
<td>Gentamicin 5/5</td>
<td>0–1.5</td>
</tr>
<tr>
<td>Kotze et al(^{22})</td>
<td>2000</td>
<td>Randomised</td>
<td>&gt; 34</td>
<td>&gt; 2500</td>
<td>4/5</td>
<td>24</td>
<td>0.2–0.2</td>
<td>No</td>
<td>Gentamicin 4/5</td>
<td>24/12</td>
</tr>
<tr>
<td>Mercado et al(^{*})</td>
<td>2001</td>
<td>Randomised</td>
<td>&gt; 34</td>
<td>&gt; 0000</td>
<td>4/5</td>
<td>24</td>
<td>0.2–0.2</td>
<td>No</td>
<td>Gentamicin 4/5</td>
<td>24/12</td>
</tr>
<tr>
<td>Kosalaraksa et al(^{22})</td>
<td>2000</td>
<td>Randomised</td>
<td>&gt; 34</td>
<td>&gt; 2500</td>
<td>4/5</td>
<td>24</td>
<td>0.2–0.2</td>
<td>No</td>
<td>Gentamicin 4/5</td>
<td>24/12</td>
</tr>
<tr>
<td>Kosalaraksa et al(^{22})</td>
<td>2000</td>
<td>Randomised</td>
<td>&gt; 34</td>
<td>&gt; 2500</td>
<td>4/5</td>
<td>24</td>
<td>0.2–0.2</td>
<td>No</td>
<td>Gentamicin 4/5</td>
<td>24/12</td>
</tr>
<tr>
<td>Kosalaraksa et al(^{22})</td>
<td>2000</td>
<td>Randomised</td>
<td>&gt; 34</td>
<td>&gt; 2500</td>
<td>4/5</td>
<td>24</td>
<td>0.2–0.2</td>
<td>No</td>
<td>Gentamicin 4/5</td>
<td>24/12</td>
</tr>
<tr>
<td>Kosalaraksa et al(^{22})</td>
<td>2000</td>
<td>Randomised</td>
<td>&gt; 34</td>
<td>&gt; 2500</td>
<td>4/5</td>
<td>24</td>
<td>0.2–0.2</td>
<td>No</td>
<td>Gentamicin 4/5</td>
<td>24/12</td>
</tr>
<tr>
<td>Kosalaraksa et al(^{22})</td>
<td>2000</td>
<td>Randomised</td>
<td>&gt; 34</td>
<td>&gt; 2500</td>
<td>4/5</td>
<td>24</td>
<td>0.2–0.2</td>
<td>No</td>
<td>Gentamicin 4/5</td>
<td>24/12</td>
</tr>
</tbody>
</table>

*Not an inclusion criterion in the trial.
Efficacy and toxicity
In only three trials were complete data on clinical efficacy reported. After the authors for the other trials had been contacted to ascertain if there were bacterial infections that the aminoglycoside had failed to cure, the complete clinical course was obtained for 555 neonates in nine trials. No deaths were reported. One trial20 reported two treatment failures, both in the TD group. This trial defined clinical response as improvement within 72 hours of treatment, but clinical improvement was not evaluated in neonates with metabolic disturbances, congenital heart disease, or Gram positive bacterial infections. Of the two neonates, one was diagnosed with bacterial meningitis and the treatment was changed to cefotaxime. The other neonate, who was treated with cloxacillin and gentamicin, had a nosocomial infection after five days of treatment. Both patients had negative blood and cerebrospinal cultures.

Nephrotoxicity was investigated in 589 neonates in 12 trials.17–24 27–30 Skopnik et al23 found alanine aminopeptidase in the urine of all 20 neonates, and Kotze et al20 found at least one raised creatinine concentration in 30 of 40 neonates. Of these, 13 of 20 were given TD and 17 of 20 were given EID.

Information on otoxicity was obtained in four trials17 18 27 30 and 210 neonates. Lundergan et al17 found one event in the EID group.

DISCUSSION
The aim of this meta-analysis was to compare the effect of EID and TD of aminoglycosides. To exclude other possible causes for differences found in pharmacokinetics, efficacy or toxicity, only trials with similar daily dose in the two groups were included. Many trials were excluded on the basis of this criterion (fig 4). Although this meta-analysis was also based on non-randomised trials, we used the QUOROM statement check list. Our findings suggest that EID of aminoglycoside in neonates is safe and effective and decreases the risk of SDCs outside the therapeutic range.

![Figure 1](http://fn.bmj.com/ArchDscChildFetalNeonatalEd: first published as 10.1136/adc.2004.056317 on 27 April 2005. Downloaded from http://fn.bmj.com/ on December 2, 2023 by guest. Protected by copyright.)

**Figure 1** Trials grouped by the peak therapeutic range. Trials accepting lower peak serum drug concentration (SDC; gentamicin/tobramycin <3 mg/l, amikacin <20 mg/l) vs trials with higher therapeutic peak range. CI, Confidence interval; EID, extended interval dosing; TD, traditional dosing, typically 2–3 mg/kg gentamicin given to neonates at dosage interval 8–24 hours.

### Table 2: Pharmacokinetics in trials included in the meta-analysis

<table>
<thead>
<tr>
<th>Trial</th>
<th>No of patients</th>
<th>Prevalence of peak SDC outside therapeutic range (outside/total [%])</th>
<th>Prevalence of trough SDC outside therapeutic range (outside/total [%])</th>
<th>Risk ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No of neonates included in the meta-analysis</td>
<td>TD group</td>
<td>EID group</td>
<td>TD group</td>
</tr>
<tr>
<td>Skopnik et al23</td>
<td>20</td>
<td>0/10 (0.0%)</td>
<td>0/10 (0.0%)</td>
<td>0/10 (0.0%)</td>
</tr>
<tr>
<td>Hayani et al22</td>
<td>24</td>
<td>0/11 (0.0%)</td>
<td>9/37 (24.3%)</td>
<td>2/27 (7.4%)</td>
</tr>
<tr>
<td>Koizue et al24</td>
<td>40</td>
<td>0/20 (0.0%)</td>
<td>9/36 (25.0%)</td>
<td>3/31 (9.7%)</td>
</tr>
<tr>
<td>Agarwal et al25</td>
<td>54</td>
<td>0/27 (0.0%)</td>
<td>2/28 (7.1%)</td>
<td>2/27 (7.4%)</td>
</tr>
<tr>
<td>Andrews et al26</td>
<td>55</td>
<td>0/27 (0.0%)</td>
<td>2/28 (7.1%)</td>
<td>2/27 (7.4%)</td>
</tr>
<tr>
<td>Chotigeat et al27</td>
<td>57</td>
<td>0/27 (0.0%)</td>
<td>2/28 (7.1%)</td>
<td>2/27 (7.4%)</td>
</tr>
<tr>
<td>Gooding et al28</td>
<td>64</td>
<td>0/27 (0.0%)</td>
<td>2/28 (7.1%)</td>
<td>2/27 (7.4%)</td>
</tr>
<tr>
<td>Kosalaraksa et al29</td>
<td>73</td>
<td>0/27 (0.0%)</td>
<td>2/28 (7.1%)</td>
<td>2/27 (7.4%)</td>
</tr>
<tr>
<td>Alassadi et al30</td>
<td>100</td>
<td>0/27 (0.0%)</td>
<td>2/28 (7.1%)</td>
<td>2/27 (7.4%)</td>
</tr>
<tr>
<td>Lundergan et al31</td>
<td>121</td>
<td>0/27 (0.0%)</td>
<td>2/28 (7.1%)</td>
<td>2/27 (7.4%)</td>
</tr>
<tr>
<td>Total</td>
<td>698</td>
<td>1/355 (25.6%)</td>
<td>28/343 (8.2%)</td>
<td>108/355 (30.4%)</td>
</tr>
</tbody>
</table>

Tests for heterogeneity between subgroups $\chi^2 = 6.1927$, df = 1, $p = 0.013$
Pharmacokinetics

The summary risk ratios for therapeutic SDCs were significantly in favour of the EID for both peak and trough SDCs. The summary peak risk ratio was more in favour of the EID in trials aiming at peak SDCs associated with an improved clinical outcome in severe infections than in trials with lower therapeutic peak range (fig 1). This supports the use of EID. When peak SDCs in trials with lower therapeutic peak range were discarded, the summary peak and trough risk ratio were within the same range in randomised trials and in trials without systematic errors as in all trials. The SDC should be assessed in EID, as 8% of the peak and 6% of the trough SDCs were outside the therapeutic range.

Efficacy and toxicity

In EID the risk of breakthrough infections has been of great concern. However, meta-analyses of trials in adults and children have shown equal or better performance in EID than in TD. This could be explained by several in vitro findings. Aminoglycosides show post-antibiotic effects and post-antibiotic leucocyte enhancement. The bacterial killing is concentration dependent and is largest at first exposure. Higher and more infrequent peak SDCs may prevent the formation of resistant mutants. 13

Figure 2  Randomised trials and results when non-randomised trials added: peak serum drug concentration (SDC). CI, Confidence interval; EID, extended interval dosing, typically 4–5 mg/kg gentamicin given to neonates at dosage interval 24 hours or longer; TD, traditional dosing, typically 2–3 mg/kg gentamicin given to neonates at dosage interval 8–24 hours.

Tests for heterogeneity between trials $\chi^2 = 19.39$, df = 11, $p = 0.054$

Figure 3  Randomised trials and results when non-randomised trials added: trough serum drug concentration (SDC). CI, Confidence interval; EID, extended interval dosing, typically 4–5 mg/kg gentamicin given to neonates at dosage interval 24 hours or longer; TD, traditional dosing, typically 2–3 mg/kg gentamicin given to neonates at dosage interval 8–24 hours.

Tests for heterogeneity between trials $\chi^2 = 15.2150$, df = 11, $p = 0.17$
shown here, EID will decrease the subtherapeutic peak.

Figure 4  Flow diagram showing the selection of trials for meta-

analysis.

development of adaptive resistance after exposure.14 As shown here, EID will decrease the subtherapeutic peak SDCs, which is a predictor of poor clinical outcome.3 As only two out of 555 neonates did not respond to the aminoglyco-
side treatment, both methods of dosing might be regarded as effective. These results should, however, be interpreted with care, as complete data on morbidity and mortality were often not reported, and the presence of persisting positive blood
cultures was seldom extractable from the trial reports.

Given the heterogeneity in the definitions and prevalence
of nephrotoxicity, it was not possible to compare the different
trials. The finding of only one instance of otoxicity in the
210 neonates tested is consistent with other trials, often
failing to identify neonatal aminoglycoside treatment as a
major cause of deafness.35 36

What is already known on this topic

- In extended interval dosing, peak serum aminoglyco-
side concentration is higher and trough serum amino-
glycoside concentration lower than in traditional
dosing.

- The neonatal daily dose and dosage interval varies
widely among guidelines, and the need to assess serum
drug concentrations is debated.

What this study adds

- In extended interval dosing, therapeutic serum amino-
glycoside concentrations are achieved more often than in
traditional dosing.

- For the peak serum drug concentration, the difference
is more pronounced in trials with therapeutic peak
range associated with improved clinical outcome.

- The results of this systematic review indicate that the
serum drug concentration should be assessed in
extended interval dosing, as 8% of the peak and 6% of
the trough serum drug concentrations were outside
the therapeutic range.

- No significant differences in clinical cure rate or toxicity
were found.

Future trials

Could these findings apply to neonates in all clinical
situations? Some of the prospective randomised trials
excluded many of the patients often found in neonatal
intensive care units, and studies comparing EID with TD in a
control group more often had wide inclusion criteria. As
treatment failure is rare, large scale studies would be needed
to study differences in clinical cure rate between EID and TD.

ACKNOWLEDGEMENTS

We thank Karianne Wiger for valuable comments during the
preparations of the final draft.

CONTRIBUTORS

EN initiated the initial design of this study and undertook the
literature search. BJJB and KOW extracted the data. LS advised on the
statistical analyses. All authors contributed to the writing of the final
draft of the manuscript. EN is guarantor.

Authors’ affiliations

E Nestaas, Department of Paediatrics, Hospital of Vestfold, Tønsberg,
Norway

E Nestaas, H-J Bangstad, K-O Wathne, Department of Paediatrics,
Ullevål University Hospital, Norway

L Sandvik, Centre for Clinical Research, Ullevål University Hospital

Funding: EN has received funding for statistics courses from the Sister
Strays legacy.

Competing interests: none declared

REFERENCES

1 Moore RD, Smith CR, Lietman PS. The association of aminoglycoside plasma
levels with mortality in patients with gram-negative bacteremia. J Infect Dis

2 Barza M, Ioannidis JP, Cappelleri JC, et al. Single or multiple daily doses of

3 Contopoulos-Ioannidis DG, Giatis ND, Baliatsa DV, et al. Extended-interval
aminoglycoside administration for children: a meta-analysis. Pediatrics

dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis
1997;24:786–95.

5 Ali MZ, Goetz MB. A meta-analysis of the relative efficacy and toxicity of
single daily dosing versus multiple daily dosing of aminoglycosides. Clin Infect
Dis 1997;24:796–809.

6 Ferris-Lisart R, Alas-Alminana M. Effectiveness and safety of once-daily
aminoglycosides: a meta-analysis. Am J Health Syst Pharm

7 Munchfeld WJ, Grayson ML, Turnidge JD. A meta-analysis of studies on the
safety and efficacy of aminoglycosides given either once daily or as divided

8 Galloe AM, Graudal N, Christensen HR, Kampmann JP. Aminoglycosides: single

Working in paediatrics and not a member of the Royal College of Paediatrics and Child Health?

Have you thought about the benefits of joining?

Benefits and entitlements of membership
- Regular mailings including quarterly newsletter
- Listed in handbook plus your own copy at no extra charge
- Representation on Council (the College’s governing body)
- Local support
- Archives of Disease in Childhood (BMJ cost to non members £206.00)
- Discount at Spring meeting
- Book club with discounts on books related to paediatrics
- CPD monitoring (fellows and associates)
- Voting at general meetings (fellows and ordinary members)
- Membership certificate (fellows and ordinary members)
- HST monitoring (ordinary members)
- Designation MRCPCH (ordinary members)
- Designation FRCPCH (fellows)

Subscriptions (inclusive of Archives)
- Junior £140.00
- Ordinary £325.00
- Fellow £380.00
- Associate £238.00

Concessionary subscriptions are available for those working part time or resident overseas.

Application forms and information on eligibility are available via www.rcpch.ac.uk or by contacting The Membership Section, Royal College of Paediatrics and Child Health, 50 Hallam Street, London W1W 6DE; tel (020) 7307 5619/20/23; fax (020) 7307 5601; email: membership@rcpch.ac.uk.

www.archdischild.com